Let's check on the charts and indicators.
Let's review the charts and indicators.
Here's our price objective for now.
Investors are increasingly looking to the companies involved in clinical trials. Here are six favorite names in this space.
The current candidates for the 2022 Tax-Loss Selling Recovery Portfolio are few and far between, with only a couple households names in the bunch.
The economics of this space is not nearly as favorable as the outcomes these drugs achieve in medical settings.
ProQR Therapeutics, Oscar Health and Hims & Hers Health appear to have promising futures.
FIGS has become the trendy play for scrubs.
To help readers navigate this mushrooming opportunity, I've put together a list of the top corporate leaders in the field.
Continue to hold previously recommended longs.